contraindications for glp 1 agonists Table 5 from Glucagon-Like Peptide-1 (GLP-1) Receptor Drug Class Review Benefits and Risks of GLP-1

Glatter: In practice, many patients labeled non-responders to GLP-1 therapy are experiencing incomplete dosing, early discontinuation because of gastrointestinal side effects, insufficient treatment duration, or competing metabolic drivers such as severe insulin resistance, sleep disruption, sarcopenia, or medication-associated weight gain

How do GLP-1 drugs work

doi: 10.1210/endo.142.10.8415

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index

however, it is not yet approved for use Boehringer Ingelheim, a biopharmaceutical company headquartered in Ingelheim, Germany, has announced promising results from its Phase 3 SYNCHRONIZE-1 clinical trial testing survodutide